Scientists decode cancer genes to personalize treatment

NCT ID NCT00339963

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal is to improve diagnosis and guide future therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to more precise diagnosis and personalized treatment for lymphoma, leukemia, and multiple myeloma patients.

What could go wrong

This is a retrospective observational study, not a treatment trial. It may not directly change patient care, and findings need validation in future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma leukemia lymphoid neoplasm lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Cancer Institute (NCI), 9000 Rockville Pike

    Bethesda, Maryland, 20892, United States